43.79 USD
+0.21
0.48%
At close Jul 11, 4:00 PM EDT
After hours
43.79
+0.00
0.00%
1 day
0.48%
5 days
4.51%
1 month
10.25%
3 months
12.98%
6 months
-30.44%
Year to date
-25.54%
1 year
-31.28%
5 years
10.92%
10 years
108.92%
 

About: Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.

Employees: 11,396

0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 7 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

63% more first-time investments, than exits

New positions opened: 98 | Existing positions closed: 60

19% more repeat investments, than reductions

Existing positions increased: 145 | Existing positions reduced: 122

8% more funds holding

Funds holding: 364 [Q4 2024] → 394 (+30) [Q1 2025]

1.47% less ownership

Funds ownership: 80.85% [Q4 2024] → 79.38% (-1.47%) [Q1 2025]

29% less funds holding in top 10

Funds holding in top 10: 7 [Q4 2024] → 5 (-2) [Q1 2025]

30% less capital invested

Capital invested by funds: $7.19B [Q4 2024] → $5.03B (-$2.16B) [Q1 2025]

54% less call options, than puts

Call options by funds: $6.24M | Put options by funds: $13.6M

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$40
9%
downside
Avg. target
$48
9%
upside
High target
$60
37%
upside

7 analyst ratings

positive
43%
neutral
57%
negative
0%
B of A Securities
Derik De Bruin
14%upside
$50
Buy
Maintained
26 Jun 2025
Citigroup
Patrick Donnelly
9%downside
$40
Neutral
Downgraded
22 May 2025
UBS
Dan Leonard
3%upside
$45
Neutral
Maintained
8 May 2025
Barclays
Luke Sergott
5%upside
$46
Overweight
Maintained
8 May 2025
Goldman Sachs
Matthew Sykes
3%upside
$45
Neutral
Maintained
8 May 2025

Financial journalist opinion

Based on 3 articles about BRKR published over the past 30 days

Positive
Zacks Investment Research
1 week ago
BRKR Stock Gains Following the Multi-System Advanced Packaging Order
Bruker ships and installs its 15th InSight WLI system as part of a 27-optical metrology unit order tied to AI chip packaging demand.
BRKR Stock Gains Following the Multi-System Advanced Packaging Order
Neutral
Business Wire
2 weeks ago
Bruker Experiences Growth in Semiconductor Advanced Packaging Market Fueled by AI Demands
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced the shipment and installation of the 15th InSight WLI 3D optical metrology system to a leading semiconductor manufacturer. The installation is part of a larger order from this semiconductor manufacturer for 27 Bruker optical metrology systems in 2025. This reflects the growing demand for high-performance metrology that can support advanced packaging requirements in the latest generation AI high-performance chip.
Bruker Experiences Growth in Semiconductor Advanced Packaging Market Fueled by AI Demands
Negative
Zacks Investment Research
2 weeks ago
New Strong Sell Stocks for June 23rd
ARCC, BIDU and BRKR have been added to the Zacks Rank #5 (Strong Sell) List on June 23 2025.
New Strong Sell Stocks for June 23rd
Positive
Zacks Investment Research
1 month ago
Bruker Stock Set to Gain From Acquisition of Austria's biocrates
BRKR strengthens its MS-based metabolomics platform with the biocrates deal, boosting investor sentiment.
Bruker Stock Set to Gain From Acquisition of Austria's biocrates
Neutral
Business Wire
1 month ago
Bruker Applied MS Unveils Strategic Innovations at ASMS 2025, Showcasing Advances in DART Technology for TDM and DoA Analysis and Launching timsMetabo™ for PFAS and Environmental Contaminant Detection
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (NASDAQ: BRKR) today announced that its Applied Mass Spectrometry (Applied MS) division will present a powerful lineup of innovations at the 73rd American Society for Mass Spectrometry (ASMS) Conference, taking place June 1–5, 2025, in Baltimore, Maryland. These developments reflect Bruker's continued investment in applied markets, particularly in therapeutic drug monitoring (TDM), drugs of abuse (DoA) analysis and environmental analysis. Br.
Bruker Applied MS Unveils Strategic Innovations at ASMS 2025, Showcasing Advances in DART Technology for TDM and DoA Analysis and Launching timsMetabo™ for PFAS and Environmental Contaminant Detection
Neutral
Business Wire
1 month ago
Bruker Announces Acquisition of biocrates, a Leader in Mass Spectrometry-based Quantitative Metabolomics
INNSBRUCK, Austria--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (NASDAQ: BRKR) today announced the acquisition of biocrates life sciences ag, located in Innsbruck, Austria. Financial terms were not disclosed. biocrates is a global leader in mass spectrometry (MS)-based quantitative metabolite and lipid analysis kits, assays, software and services that make standardized metabolomics accessible to laboratories worldwide. The biocrates kits cover over 1,000+ metabolites from more than 40 metabolite classe.
Bruker Announces Acquisition of biocrates, a Leader in Mass Spectrometry-based Quantitative Metabolomics
Neutral
Business Wire
1 month ago
Bruker Launches New timsUltra AIP System with Further Enhanced, Extreme Sensitivity for Single-Cell Proteomics, FNA Biopsy Immunopeptidomics and Metaproteomics
BALTIMORE--(BUSINESS WIRE)---- $BRKR #BRKR--At the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), Bruker Corporation (Nasdaq: BRKR) today announced significant further advances in ultra-high sensitivity 4D-Proteomics™ with the introduction of the timsUltra AIP mass spectrometer. Its innovative, breakthrough Athena Ion Processor (AIP) technology further boosts the extreme sensitivity of timsTOF Ultra PASEF® methods for key biological and clinical research problems with very low sample amounts. N.
Bruker Launches New timsUltra AIP System with Further Enhanced, Extreme Sensitivity for Single-Cell Proteomics, FNA Biopsy Immunopeptidomics and Metaproteomics
Neutral
Business Wire
1 month ago
Bruker Unveils New proteoElute™ nanoLC System and PepSep® Advanced nLC Columns for up to 50% Improved Peptide Sensitivity
BALTIMORE--(BUSINESS WIRE)---- $BRKR #BRKR--At the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), Bruker Corporation (Nasdaq: BRKR) today announced the new proteoElute nanoLC system, featuring ceramic valves, proteoTrap trapping columns, and next-generation PepSep Advanced nLC columns, further enhancing robustness, sensitivity and proteome coverage in ultra-sensitive proteomics workflows. A. Bruker Introduces the proteoElute Next-Generation Nanoflow LC System for Robust, Ultra-Sensitive Proteom.
Bruker Unveils New proteoElute™ nanoLC System and PepSep® Advanced nLC Columns for up to 50% Improved Peptide Sensitivity
Neutral
Business Wire
1 month ago
Bruker Corporation to Present at the Jefferies Global Healthcare Conference
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced today that its senior leadership will participate in the Jefferies Global Healthcare Conference in New York City with a fireside chat presentation scheduled for Wednesday, June 4th, 2025 at 5:30 PM Eastern Time. A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. A replay of the presentation will be posted in the “Events &.
Bruker Corporation to Present at the Jefferies Global Healthcare Conference
Neutral
Business Wire
1 month ago
Bruker Launches Revolutionary timsOmniTM Mass Spectrometer
BALTIMORE--(BUSINESS WIRE)---- $BRKR #BRKR--For the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), Bruker Corporation (Nasdaq: BRKR) announced the launch of the timsOmni™ system, a transformative new timsTOF-based mass spectrometer designed for scientific, drug discovery, and clinical researchers, as well as for advanced QC on biologics, offering deep structural insights into the functional or pathological proteoforms or oligonucleotides. Multimodal eXd trapping with precise electron energy con.
Bruker Launches Revolutionary timsOmniTM Mass Spectrometer
Charts implemented using Lightweight Charts™